



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

Mail Stop 4645

February 14, 2017

Jeffrey A. Munsie  
General Counsel  
Merrimack Pharmaceuticals, Inc.  
One Kendall Square, Suite B7201  
Cambridge, Massachusetts 02139

**Re: Merrimack Pharmaceuticals, Inc.  
Preliminary Proxy Statement on Schedule 14A  
Filed January 24, 2017  
File No. 001-35409**

Dear Mr. Munsie:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

/s/ Joseph McCann for

Suzanne Hayes  
Assistant Director  
Office of Healthcare and Insurance

Cc: Katherine D. Ashley  
Graham Robinson  
Skadden, Arps, Slate, Meagher & Flom LLP